Bromazolam Powder

What is 5c-akb48?

5F-AKB-48(5F-APINACA) Powder is a synthetic cannabinoid which is indazole based. This component is being developed from an amazing series of different compounds which are making it an effective component to utilize for various purposes in the best possible way. More interestingly this component also contains the cannabinoid’s agonists receptors. It is an amazing fact to know that the structurally 5C-AKB48 is quite similar to the 5F-AKB48. Even more, the component is also being recognized for similar effects and similar potency in an effective way. Although, generally this component is being used for research purposes just like another synthetic cannabinoid which is named as 5C-ABP. However, most of the people around the world are also using these synthetic cannabinoids to experience the amazing effects of the 5C-AKB48. Description: 5F-APINACA (5F-AKB-48) is an analogue of APINACA (AKB-48) fluorinated on the terminal carbon of the pentyl side chain. It belongs to the category of synthetic cannabinoid receptor agonists (SCRAs), which have affinity for CB1 and CB2 receptors with activation of the former accounting for the psychoactive effects of these substances. 5F-APINACA is a psychoactive substance and has effects similar to Δ9-THC, which, in accordance with the Convention on Psychotropic Substances of 1971, is listed as Schedule I substance. 5F-APINACA binds with nanomolar affinity to CB1 and CB2 receptors (Ki -value of 1.94 and 0.27 nM, respectively), i.e. with a two-fold and 265-fold higher affinity as compared to THC. 5F-APINACA stimulates CB1-induced [35S]GTPγS binding with high potency and efficacy, and at 0.1 mg/kg i.v. it increases dopamine transmission in the nucleus accumbens. 5F-APINACA is mainly metabolized by hydroxylation and loss of the fluorine from the N-pentyl side chain. Detailed information on the toxic effects of 5F-APINACA is not available. In general, SCRAs may produce nausea, vomiting, agitation, hallucinations, panic attacks, tachycardia, hypertension, and occasionally chest pain, acute psychosis, and seizures. Clinical signs of toxicity (chest pain, tachycardia, hypertension, and agitation) following smoking of 5F-APINACA usually resolve within 4 to 10 h and may require treatment with benzodiazepines. 5F-APINACA smoking has been associated with myocardial infarction. One non-fatal case was reported in a young man following smoking of 5F-APINACA 4 h before the onset of chest pain. Five similar cases were reported after use of other adamantyl-substituted SCRAs. Long term use of 5F-APINACA is characterized by loss of appetite, cognitive impairment, breathlessness, cardiac conditions requiring medication, skin ablations, tooth decay, lethargy, apathy, tremors and insomnia, which are all exacerbated when attempting to reduce use. Studies on abuse and dependence potential of 5F-APINACA have not been performed, but users reported a rapidly developing dependence (tolerance, compulsive re-dosing, craving). A variety of withdrawal symptoms have been reported, such as chest pains and pressure, tachycardia and palpitations, ongoing insomnia (for over 3 weeks), anxiety, agitation and paranoia. No therapeutic or medical use has been described for 5F-APINACA and 5F-APINACA is neither marketed as medicinal product, nor used for industrial purposes. For recreational use, herbs containing cannabinoids such as 5F-APINACA are smoked, often mixed with tobacco in joints, bongs and pipes. 5F-APINACA has been detected in commercial products send to or sold in Czech Republic, France, Portugal, the US and the UK. 5F-APINACA is not controlled world-wide so that in various countries products containing 5F-APINACA are legally marketed in head shops and via the Internet. In other countries, like Bulgaria, Brazil, some European member states (e.g., France, Latvia, the UK), Korea, and the US, 5F-APINACA was detected in seizures by customs or police. 5F-APINACA is a controlled substance in countries, like Australia, Canada, Germany, Czech Republic, China, Denmark, Latvia, Estonia, Moldova, New Zealand, the UK and the US.